

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**HUA MEDICINE**

**華領醫藥**

*(Incorporated in the Cayman Islands with limited liability)*

*(stock code: 2552)*

**SUPPLEMENTAL ANNOUNCEMENT  
IN RELATION TO THE INTERIM RESULTS ANNOUNCEMENT  
FOR THE SIX MONTHS ENDED JUNE 30, 2019**

The board of directors (the “**Board**”) of Hua Medicine (the “**Company**”, and its subsidiaries, the “**Group**”) makes this supplemental announcement further to the Company’s announcement dated August 15, 2019 in relation to its interim results for the six months ended June 30, 2019 (the “**Announcement**”). Unless otherwise defined, capitalized terms used in this supplemental announcement shall have the same meanings as those defined in the Announcement.

In addition to the information disclosed in the Announcement, the Company wishes to provide the shareholders of the Company and the potential investors with the following supplementary information:

**Subsequent Event**

Except as disclosed in the Announcement, no important events affecting the Group have occurred subsequent to June 30, 2019.

By Order of the Board  
**Dr. Li Chen**  
*Chief Executive Officer and  
Executive Director*

Hong Kong, August 23, 2019

*As at the date of this announcement, the Board of Directors comprises Dr. Li Chen and Mr. George Chien Cheng Lin as executive Directors; Mr. Robert Taylor Nelsen and Dr. Lian Yong Chen as non-executive Directors; and Mr. Walter Teh-ming Kwauk, Mr. William Robert Keller, Mr. Junling Liu and Mr. Yiu Wa Alec Tsui as independent non-executive Directors.*